

ADHD Guideline Committee Meeting 13

Date and Time: Tuesday 04 July 2017, 10:00-16:30

Place: Boardroom, National Guideline Centre

Minutes: Draft

Present:	Gillian Baird (GB)	Professor of Paediatric Neurodisability and Consultant Developmental Paediatrician, Chair
	Emily Simonoff (ES)	Professor of Child & Adolescent Psychiatry, Clinical Specialist
	Philip Asherson (PA)	Professor of Psychiatry and Honorary Consultant Psychiatrist
	Marios Adamou (MA)	Consultant Psychiatrist (adults) and Visiting Professor
	Polly Branney (PB)	General Practitioner
	Poppy Ellis Logan (PEL)	Lay Member
	Jean Fitzpatrick (JF)	Lay Member
	Gisli Gudjonsson (GG)	Professor of Psychology
	Chris Hollis (CH)	Professor of Child & Adolescent Psychiatry and Consultant in Developmental Neuropsychiatry
	Nicole Horwitz (NH)	Consultant Community Paediatrician
	Jen Lewis-Neill (JLN)	Clinical Lead/Independent Nurse Prescriber
	Karen Pratt (KP)	Paediatric Nurse Specialist for Neurodisability
	Jonathan Rackham (JR)	Lay Member
	Kapil Sayal (KS)	Professor of Child & Adolescent Psychiatry and Honorary Consultant Psychiatrist
	David Traxson (DT)	Educational Psychologist
	Jody Warner-Rogers (JWR)	Consultant Clinical Psychologist and Paediatric Neuropsychologist
	Ian Wong (IW)	Professor of Pharmacy Practice and Medicine Evaluation
	NICE team	
	Anne-Louise Clayton (ALC)	Senior Medical Editor
	Ben Doak (BD)	Guidelines Commissioning Manager
	Ian Mather (IM)	Business Analyst
	NIHR	
	Jemma Kwint (JK)	Scientific Advisor (items 4-7)
	NGC technical team	
	Margaret Constanti (MC)	Senior Health Economist
	James Gilbert (JG)	Senior Research Fellow
	Samantha Jones (SJ)	Project Manager (notes)
	Kate Kelley (KK)	Guideline Lead
	Rafina Yarde (RY)	Research Fellow
	Apologies	
	Rebecca Boffa (RB)	Research Fellow, NGC

Notes

1. The Chair welcomed the group to the thirteenth meeting of this GC. Apologies were received from RB and KB.
2. The Chair reviewed and requested updates to the declarations of interest register. The Chair declared that in relation to previous declarations recorded in the DOI register, for this meeting, the following actions should apply:
 - Philip Asherson should withdraw from discussions on the pharmacological efficacy review and recommendations.
 The following new declarations were received for this meeting:

GC Declarations of Interest			
N.B. The Chair and GC members were recruited to this guideline using NICE DOI policy published September 2014.			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
PA	<ol style="list-style-type: none"> 1. 24th May Shire sponsored meeting. Gave general educational talk in Oslo on adult ADHD. Discussed lifetime course of adult ADHD, mind wandering and the effects of cannabinoids. A fee for this work was paid to King's College London. 2. 26th May Estonian Psychiatric Association meeting. Gave talk on the diagnosis and clinical management of ADHD in adults to the Estonian Psychiatric Association. A fee for this work was paid to King's College London. 3. 30-31st May Lundbeck advisory board. Participated in a scientific advisory board for Lundbeck advising on new studies of the use of a novel compound for potential use in a number of different psychiatric conditions including ADHD. A fee for this work was paid to King's College London. 4. 20th June Dundee and Angus Service User Support Group. Talk on mind wandering in adult ADHD. No fee paid for this work. 	<ol style="list-style-type: none"> 1. Non-personal financial specific 2. Non-personal financial specific 3. Non-personal financial specific 4. Non-personal financial non-specific 	<ol style="list-style-type: none"> 1. Declare and participate 2. Declare and participate 3. Declare and participate 4. Declare and participate
CH			
ES			
NICE DOI policy classifications are: <ul style="list-style-type: none"> • Personal financial specific • Personal financial non-specific 			

- Personal non-financial specific
- Personal non-financial non-specific
- Non-personal financial specific
- Non-personal financial non-specific

3. The meeting notes and NICE minutes of the last meeting were reviewed by the committee. Minor amendments were required. The notes and NICE minutes were then agreed as a true and accurate record of the meeting.
4. IM gave a presentation on the role and next steps of the NICE resource impact team.
5. The GC reviewed and amended the draft recommendations. PA left the room for discussions on the first-line pharmacological treatment recommendations.
6. The GC discussed research recommendation priorities for inclusion in the guideline.
7. AOB: Action points were assigned and next steps discussed.

Date, time and venue of the next meeting

Committee Meeting 14: Thursday 16 November, 10:00-16:00, NGC Boardroom, 180 Great Portland Street, London W1W 5QZ